GALWAY, Ireland, June 3, 2026
Medtronic has announced a series of major regulatory and clinical milestones aimed at significantly expanding the capabilities of its Hugo™ robotic-assisted surgery (RAS) system in the United States. The company confirmed the submission of multiple FDA 510(k) applications covering general surgery, gynecologic surgery, and the LigaSure™ RAS Maryland instrument, while also receiving FDA 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for robotic-assisted ventral hernia repair procedures. These developments represent a significant step forward in Medtronic’s strategy to broaden access to robotic-assisted surgery and strengthen its position in the rapidly growing surgical robotics market. Building on the Hugo system’s FDA clearance for urologic procedures received in late 2025, the latest milestones underscore the company’s commitment to creating a comprehensive surgical ecosystem that integrates advanced instruments, intelligent technologies, and minimally invasive surgical techniques to improve patient outcomes and healthcare efficiency.
Hugo Robotic System Advances into General and Gynecologic Surgery
The newly submitted FDA 510(k) applications seek to expand the Hugo robotic-assisted surgery platform into two of the largest and fastest-growing surgical specialties: general surgery and gynecology. If approved, these indications would substantially broaden the system’s clinical utility in the U.S. market, enabling surgeons to perform a wider range of minimally invasive procedures using robotic technology. Medtronic noted that the Hugo platform is already used in major international markets for these surgical applications and has accumulated extensive real-world experience across more than 35 countries and five continents.
The system has supported tens of thousands of procedures globally and is backed by hundreds of independently published scientific studies evaluating its safety and effectiveness. Expanding into these high-volume specialties could significantly increase adoption of the Hugo platform as hospitals and ambulatory surgical centers continue to invest in robotic technologies that improve precision, consistency, and patient recovery outcomes.
New Technologies Strengthen Robotic Surgery Ecosystem
Advertisement
A key component of Medtronic’s latest announcement is the FDA submission for the LigaSure™ RAS Maryland instrument, a robotic adaptation of the company’s widely used vessel-sealing technology. Designed exclusively for use with the Hugo RAS platform and the Valleylab™ FT10 energy system, the instrument integrates a technology that has already been utilized in more than 35 million surgical procedures worldwide. The addition of LigaSure functionality provides surgeons with enhanced control during complex operations and strengthens the procedural versatility of the Hugo platform.
Medtronic also announced FDA clearance for ProGrip™ Advanced mesh, specifically engineered for robotic-assisted ventral hernia repair procedures. The new mesh technology has been optimized for robotic workflows, enabling easier insertion, handling, deployment, and positioning during minimally invasive surgery. As robotic-assisted hernia repair continues to gain momentum across healthcare systems, the introduction of advanced procedure-specific tools may help improve surgical efficiency and consistency while supporting broader adoption of robotic techniques.
Clinical Progress Supports Future Growth Strategy
Further reinforcing its expansion plans, Medtronic announced completion of patient enrollment in the Embrace Gynecology Investigational Device Exemption (IDE) study, a prospective multicenter clinical trial evaluating the safety and effectiveness of the Hugo RAS system in robotic-assisted gynecologic procedures. The study successfully enrolled 70 patients across five U.S. hospitals, marking an important milestone toward future regulatory review. The completion of enrollment highlights growing clinical interest in robotic-assisted gynecologic surgery and provides an important evidence base supporting the system’s potential expansion.
As healthcare providers increasingly seek technologies capable of improving procedural precision, reducing hospital stays, and supporting minimally invasive approaches, robotic-assisted surgery continues to emerge as a critical area of innovation. Through its integrated portfolio spanning open, laparoscopic, and robotic-assisted surgery, Medtronic aims to offer healthcare systems greater flexibility while helping surgeons deliver high-quality care across diverse treatment settings. The latest regulatory filings and product clearances position the company to accelerate growth in robotic surgery and strengthen its role in shaping the future of surgical innovation.
Source: Medtronic press release
